NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of WuXi PharmaTech (Cayman) Inc. WX securities between September 1, 2015 and December 10, 2015, both dates inclusive. The lawsuit seeks to recover damages for WuXi investors under the federal securities laws.
If you wish to serve as lead plaintiff, you must move the Court no later than April 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation http://zhanginvestorlaw.com/join-action-form/?slug=wuxi-pharmatech-cayman-inc&id=1758 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756, or email info@zhanginvestorlaw.com, slee@zhanginvestorlaw.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) WuXi's public statements misrepresented and/or omitted material information that was necessary for WuXi shareholders to make an informed decision concerning whether to vote in favor of the merger between WuXi with New WuXi Life Science Limited and WuXi Merger Limited for approximately $3.62 billion; (2) defendants had plans to spin-off and publicly list WuXi's various subsidiaries in a series of highly accretive transactions; and (3) as a result, WuXi's statements about its business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class has not been certified. You may retain counsel of your choice. You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law represents investors worldwide.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
